Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 2/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595377 | 0.91 | CXCR1 (0.55) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL5594951 | 0.84 | HTT (0.71) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL6820169 | 0.81 | KMT2A (0.68) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL3710415 | 0.81 | KMT2A (0.68) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL5595104 | 0.80 | CXCR1 (0.80) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL3706043 | 0.80 | CXCR1 (0.61) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL3678982 | 0.78 | MEN1 (0.67) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL17085327 | 0.77 | HTT (0.71) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL7487840 | 0.77 | CXCR2 (0.69) | CXCR1CXCR2KMT2AMEN1MAPT | |
| SCHEMBL17287914 | 0.76 | CXCR1 (0.70) | CXCR1CXCR2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809492-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1185261-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-0896531-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020128321-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| CN-1355697-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 2002-06-26 | — | — | CN | disclosed |
| EP-1185261-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6262113-B1 | HYDROXY- OR MERCAPTO-PHENYLUREAS | SMITHKLINE BEECHAM CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6211373-B1 | Phenyl urea antagonists of the IL-8 receptor | SMITHKLINE BEECHAM CORPORATION | 2001-04-03 | — | — | US | disclosed |
| US-6180675-B1 | THERAPY FOR CHEMOKINE SENSITIVE DISEASE; USING A AROMATIC (THIO)UREA COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2001-01-30 | — | — | US | disclosed |
| WO-2000076495-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| US-6005008-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | disclosed |
| US-5886044-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0896531-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-17 | — | — | EP | disclosed |
| US-5780483-A | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0809492-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997029743-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996025157-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128321-A1 | IL-8 receptor antagonists | CXCL8, CCR8, IL1RN | CXCR1 21/4885CXCR2 15/4885KMT2A 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.